moxifloxacin has been researched along with quetiapine in 3 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (quetiapine) | Trials (quetiapine) | Recent Studies (post-2010) (quetiapine) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 56 | 0 | 28 |
| Protein | Taxonomy | moxifloxacin (IC50) | quetiapine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 3.3008 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 3.3447 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 1.5787 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 3.0007 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 2.4914 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 2.615 | |
| D(2) dopamine receptor | Homo sapiens (human) | 1.3299 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.1003 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.4208 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.4264 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.4293 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.0966 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.1178 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 3.3008 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 1.4264 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.0396 | |
| D(3) dopamine receptor | Homo sapiens (human) | 1.1632 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.2135 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.33 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 5.7772 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 2.2935 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sen, S; Sinha, N | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for moxifloxacin and quetiapine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for moxifloxacin and quetiapine
| Article | Year |
|---|---|
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |